- Telehealth visits
- Insurance plan information
Adil I. Daud, MBBS
Medical Oncology (Melanoma and Skin Cancer)- Telehealth visits
- Insurance plan information
Adil I. Daud, MBBS
Medical Oncology (Melanoma and Skin Cancer)- Telehealth visits
- Insurance plan information
On this page
About me
Dr. Adil Daud, an oncologist, specializes in melanoma and other skin cancers. He is co-director of the Melanoma Center. In addition to caring for patients, he directs research to better understand the biology of melanoma and to develop new treatments. He has developed and led many clinical trials that have expanded the use of gene therapy for melanoma.
Daud earned a medical degree at the Government Medical College, Nagpur. He completed both an internship and a residency in internal medicine at Indiana University School of Medicine, followed by a fellowship in hematology-oncology at Memorial Sloan Kettering Cancer Center. Prior to joining UCSF Medical Center, he was a researcher at the Moffitt Cancer Center in Tampa, Florida, for seven years.
Daud has won numerous awards, including a Young Investigator Award from the American Society of Clinical Oncology and selection as a Castle Connolly Top Doctor.
Education & training
Board certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Hematology - Oncology, Memorial Sloan-Kettering Cancer Center
Residency
- Internal Medicine, Indiana University Hospital
Degree
- MBBS, Government Medical College
Academic title
- Clinical Professor
My expertise
Locations
Advanced skin cancer was once a death sentence. Immunotherapy Is changing that.
My research
Clinical trials
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsOpens in a new window
Recruiting
To determine the safety and tolerability of oral administration of KIN-2787 including dose-limiting toxicities (DLTs), and to identify the maximum tolerated do...SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaOpens in a new window
Recruiting
progression-free survival (PFS), centrally assessed (by blinded independent central review) using RECIST 1.1ACTengine® IMA203 Combined With mRNA-4203Opens in a new window
Recruiting
Number of DLTs will be used to determine the maximum tolerated dose (MTD) and/or recommended dose for extension (RDE) after treatment with IMA203 product in co...
Publications
Showing 1-6 of 88 reviews
- August 29, 20265 out of 5 Stars
Very professional and to the point
- August 28, 20265 out of 5 Stars
Truly a great and well-informed discussion from start to finish.
- August 24, 20265 out of 5 Stars
Doctor provides excellent clinical care, discusses current research when appropriate, has invited me to appropriate zoom expert discussions, communicates well both clinically and as a caring person.
- August 22, 20264 out of 5 Stars
He paused the appt several times to answer a phone call.
- August 7, 20265 out of 5 Stars
Dr Daud has been helping me with my melanoma nearly a decade now. Professional and personable. You cant be a better provider. Works with you and plans for the next steps to keep me at my best health Also 5 Stars :)
- August 3, 20265 out of 5 Stars
All courteous, thoughtful, helpful.
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.